DZ2889A1 - 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant. - Google Patents
4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.Info
- Publication number
- DZ2889A1 DZ2889A1 DZ990189A DZ990189A DZ2889A1 DZ 2889 A1 DZ2889 A1 DZ 2889A1 DZ 990189 A DZ990189 A DZ 990189A DZ 990189 A DZ990189 A DZ 990189A DZ 2889 A1 DZ2889 A1 DZ 2889A1
- Authority
- DZ
- Algeria
- Prior art keywords
- tetrahydroquinolines
- carboxyamino
- methyl
- preparation
- pharmaceutical compositions
- Prior art date
Links
- LVHVPFOLBJZHDN-UHFFFAOYSA-N (2-methyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid Chemical class C1=CC=C2NC(C)CC(NC(O)=O)C2=C1 LVHVPFOLBJZHDN-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10092998P | 1998-09-17 | 1998-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DZ2889A1 true DZ2889A1 (fr) | 2003-12-15 |
Family
ID=22282259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DZ990189A DZ2889A1 (fr) | 1998-09-17 | 1999-09-17 | 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6147090A (de) |
| EP (1) | EP1114033B1 (de) |
| JP (1) | JP3655193B2 (de) |
| AR (1) | AR021482A1 (de) |
| AT (1) | ATE277906T1 (de) |
| AU (1) | AU5439899A (de) |
| BR (1) | BR9913842A (de) |
| CA (1) | CA2344556A1 (de) |
| CO (1) | CO5150220A1 (de) |
| DE (1) | DE69920727T2 (de) |
| DK (1) | DK1114033T3 (de) |
| DZ (1) | DZ2889A1 (de) |
| ES (1) | ES2228086T3 (de) |
| GT (1) | GT199900149A (de) |
| HN (1) | HN1999000155A (de) |
| MA (1) | MA26687A1 (de) |
| MY (1) | MY121838A (de) |
| PA (1) | PA8481501A1 (de) |
| PE (1) | PE20001048A1 (de) |
| PT (1) | PT1114033E (de) |
| SI (1) | SI1114033T1 (de) |
| SV (1) | SV1999000149A (de) |
| TN (1) | TNSN99172A1 (de) |
| TW (1) | TWI232859B (de) |
| WO (1) | WO2000017166A1 (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| ATE524163T1 (de) | 2000-04-10 | 2011-09-15 | Teva Pharma | Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| PT1355644E (pt) | 2001-01-26 | 2006-11-30 | Schering Corp | Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| RS20100015A (sr) | 2001-01-26 | 2010-12-31 | Schering Corporation | Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije |
| WO2002078625A2 (en) * | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
| SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| TNSN03139A1 (fr) * | 2001-06-21 | 2005-12-23 | Pfizer Prod Inc | Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle |
| JP4547148B2 (ja) | 2001-06-22 | 2010-09-22 | ベンド・リサーチ・インコーポレーテッド | 非晶質薬剤の吸着物の医薬組成物 |
| EP1269994A3 (de) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
| MXPA03011784A (es) * | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
| EP1429756B1 (de) | 2001-09-21 | 2006-11-22 | Schering Corporation | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| IL162533A0 (en) * | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| PL371416A1 (en) * | 2002-02-01 | 2005-06-13 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| WO2003063833A1 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| ES2277142T3 (es) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
| PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| CA2500083A1 (en) * | 2002-10-21 | 2004-04-29 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
| JP2006508188A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
| WO2004056727A2 (en) * | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| EP1961419B1 (de) | 2002-12-20 | 2010-03-24 | Pfizer Products Inc. | Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| DE602004016123D1 (de) | 2003-03-07 | 2008-10-09 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| PT1603553E (pt) | 2003-03-17 | 2012-02-03 | Japan Tobacco Inc | Composições farmacêuticas de inibidores de cetp |
| AU2004222436A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| CN1812983A (zh) | 2003-05-30 | 2006-08-02 | 兰贝克赛实验室有限公司 | 取代的吡咯衍生物及其作为hmg－co抑制剂的用途 |
| MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| WO2005030754A1 (en) | 2003-09-24 | 2005-04-07 | Janssen Pharmaceutica, N.V. | Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| RU2330682C2 (ru) | 2003-09-26 | 2008-08-10 | Джапан Тобакко Инк. | Способ ингибирования продуцирования остаточных липопротеинов |
| PL1670768T3 (pl) * | 2003-10-08 | 2010-01-29 | Lilly Co Eli | Związki i sposoby leczenia dyslipidemii |
| EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
| EA200601785A1 (ru) | 2004-03-26 | 2007-02-27 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| WO2006004903A2 (en) * | 2004-06-28 | 2006-01-12 | Atherogenics, Inc. | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| WO2006069162A1 (en) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
| EP2548894A1 (de) | 2005-02-03 | 2013-01-23 | Bend Research, Inc. | Pharmazeutische Zusammensetzungen mit erhöhter Leistung |
| BRPI0608553A2 (pt) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| SG166829A1 (en) | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| BRPI0706623A2 (pt) | 2006-01-18 | 2011-04-12 | Schering Corp | moduladores de receptor canabinóide |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| WO2007090749A2 (en) * | 2006-02-07 | 2007-08-16 | F. Hoffmann-La Roche Ag | Benzamide and heteroarene derivatives as cetp inhibitors |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| TW200808731A (en) * | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| WO2008010087A2 (en) * | 2006-07-14 | 2008-01-24 | Ranbaxy Laboratories Limited | Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| MX2009010962A (es) | 2007-04-13 | 2009-12-16 | Kowa Co | Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo. |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| EP2548874A3 (de) | 2007-06-28 | 2013-05-15 | Intervet International B.V. | Substituierte Piperazine als CB1-Antagonisten |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
| US20110065671A1 (en) | 2008-05-19 | 2011-03-17 | Harris Joel M | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| AU2009330206A1 (en) | 2008-12-23 | 2011-07-07 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives as GPCR modttlators for use in the treatment of obesity and diabetes |
| WO2010075271A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| WO2010114957A1 (en) | 2009-04-03 | 2010-10-07 | Schering Corporation | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| CA2778684A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| US8912206B2 (en) | 2009-11-23 | 2014-12-16 | Merck Sharp & Dohme Corp. | Pyrimidine ether derivatives and methods of use thereof |
| US20120232073A1 (en) | 2009-11-23 | 2012-09-13 | Santhosh Francis Neelamkavil | Fused bicyclic pyrimidine derivatives and methods of use thereof |
| WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| EP3186242B1 (de) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase |
| CN112823006B (zh) * | 2018-10-17 | 2024-09-17 | 杜克大学 | 用作神经保护剂的醌还原酶2抑制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
| US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| JPH0676403B2 (ja) * | 1991-01-18 | 1994-09-28 | エスエス製薬株式会社 | 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤 |
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-07 US US09/391,273 patent/US6147090A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481501A patent/PA8481501A1/es unknown
- 1999-09-09 HN HN1999000155A patent/HN1999000155A/es unknown
- 1999-09-10 JP JP2000574076A patent/JP3655193B2/ja not_active Expired - Fee Related
- 1999-09-10 BR BR9913842-5A patent/BR9913842A/pt not_active Application Discontinuation
- 1999-09-10 DK DK99940421T patent/DK1114033T3/da active
- 1999-09-10 DE DE69920727T patent/DE69920727T2/de not_active Expired - Fee Related
- 1999-09-10 WO PCT/IB1999/001529 patent/WO2000017166A1/en not_active Ceased
- 1999-09-10 MY MYPI99003922A patent/MY121838A/en unknown
- 1999-09-10 PE PE1999000923A patent/PE20001048A1/es not_active Application Discontinuation
- 1999-09-10 PT PT99940421T patent/PT1114033E/pt unknown
- 1999-09-10 SI SI9930672T patent/SI1114033T1/xx unknown
- 1999-09-10 CO CO99057639A patent/CO5150220A1/es unknown
- 1999-09-10 AR ARP990104556A patent/AR021482A1/es active IP Right Grant
- 1999-09-10 AU AU54398/99A patent/AU5439899A/en not_active Abandoned
- 1999-09-10 GT GT199900149A patent/GT199900149A/es unknown
- 1999-09-10 AT AT99940421T patent/ATE277906T1/de not_active IP Right Cessation
- 1999-09-10 ES ES99940421T patent/ES2228086T3/es not_active Expired - Lifetime
- 1999-09-10 CA CA002344556A patent/CA2344556A1/en not_active Abandoned
- 1999-09-10 TW TW088115690A patent/TWI232859B/zh not_active IP Right Cessation
- 1999-09-10 EP EP99940421A patent/EP1114033B1/de not_active Expired - Lifetime
- 1999-09-10 SV SV1999000149A patent/SV1999000149A/es not_active Application Discontinuation
- 1999-09-13 MA MA25764A patent/MA26687A1/fr unknown
- 1999-09-13 TN TNTNSN99172A patent/TNSN99172A1/fr unknown
- 1999-09-17 DZ DZ990189A patent/DZ2889A1/xx active
-
2000
- 2000-09-27 US US09/671,400 patent/US6395751B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE277906T1 (de) | 2004-10-15 |
| AU5439899A (en) | 2000-04-10 |
| MY121838A (en) | 2006-02-28 |
| PE20001048A1 (es) | 2000-10-17 |
| CO5150220A1 (es) | 2002-04-29 |
| DE69920727D1 (en) | 2004-11-04 |
| GT199900149A (es) | 2001-03-03 |
| TWI232859B (en) | 2005-05-21 |
| WO2000017166A1 (en) | 2000-03-30 |
| US6147090A (en) | 2000-11-14 |
| CA2344556A1 (en) | 2000-03-30 |
| SI1114033T1 (en) | 2005-02-28 |
| JP2002526477A (ja) | 2002-08-20 |
| TNSN99172A1 (fr) | 2005-11-10 |
| EP1114033B1 (de) | 2004-09-29 |
| MA26687A1 (fr) | 2004-12-20 |
| PT1114033E (pt) | 2004-12-31 |
| HN1999000155A (es) | 2000-01-12 |
| ES2228086T3 (es) | 2005-04-01 |
| DE69920727T2 (de) | 2006-03-09 |
| DK1114033T3 (da) | 2004-12-20 |
| JP3655193B2 (ja) | 2005-06-02 |
| BR9913842A (pt) | 2001-06-12 |
| SV1999000149A (es) | 2000-07-06 |
| EP1114033A1 (de) | 2001-07-11 |
| AR021482A1 (es) | 2002-07-24 |
| PA8481501A1 (es) | 2001-12-14 |
| US6395751B1 (en) | 2002-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2465A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant. | |
| DZ2773A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| MA26687A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2962A1 (fr) | Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant. | |
| FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DZ2745A1 (fr) | BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2128A1 (fr) | Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2300A1 (fr) | Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2299A1 (fr) | Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2753A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant. | |
| DZ2197A1 (fr) | Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2045A1 (fr) | Amides thérapeutiques, procédé pour leur préparation et compositions les contenant. | |
| MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26686A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26598A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant | |
| DZ2358A1 (fr) | Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| DZ1957A1 (fr) | Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| MA26490A1 (fr) | Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant. | |
| DZ2414A1 (fr) | 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. |